Clinical trial NCT02797964: A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
Official title: A Phase 1/2 Trial of SRA737 (a Chk1 Inhibitor) Administered Orally in Subjects With Advanced Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
Keywords: Replication stress
Advanced solid tumors
CCNE1
TP53
BRCA1
BRCA2
MYC
RAD50
Fanconi anemia
Cell cycle
Metastatic Colorectal Cancer
Platinum-Resistant or Intolerant High Grade Serious Ovarian Cancer
Advanced Non-Small Cell Lung Cancer
Metastatic Castration-Resistant Prostate Cancer
Head and Neck Squamous Cell Carcinoma
Squamous Cell Carcinoma of the Anus
Phase 1
Phase 2
Dose escalation
Chk1 inhibitor
Checkpoint kinase 1
Synthetic lethality
Next-Generation Sequencing
Genetic biomarkers
Lead sponsor: Sierra Oncology LLC - a GSK company
Sponsor class: INDUSTRY
First posted: 2016-06-14
Enrollment: 107
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: The purpose of this clinical study is to establish the safety profile, determine the maximum tolerated dose (MTD) and recommend a Phase 2 dose and schedule of SRA737; and to evaluate the efficacy of SRA737 in prospectively-selected subjects with genetically-defined tumors that harbor genomic alterations linked to increased replication stress and that are hypothesized to be more sensitive to checkpoint kinase 1 (Chk1) inhibition via synthetic lethality. Specific cancer indications that frequently harbor these genetic mutations will be studied.

Detailed description: SRA737 is a potent, highly selective, orally bioavailable small molecule inhibitor of Chk1, a key regulator of cell cycle progression and the DNA Damage Response (DDR) replication stress response. In cancer cells, intrinsic replication stress (RS) is induced by factors such as oncogenes (e.g., CCNE1 or MYC), genetic mutations in DNA repair machinery (e.g. BRCA1 or FANCA), genetic mutations leading to a dysregulated cell cycle (e.g., TP53 or RAD50) or other genomic alterations. This replication stress results in persistent DNA damage and genomic instability, leading to an increased dependency on Chk1 for survival. Targeted inhibition of Chk1 by SRA737 may therefore be synthetically lethal to cancer cells with elevated intrinsic RS.

This study has been designed to: establish the safety profile; determine the pharmacokinetic profile; identify the optimal dose, schedule, and MTD; obtain preliminary evidence of activity; and evaluate SRA737's efficacy in prospectively-selected subjects with tumors that harbor genomic alterations linked to increased replication stress and that are hypothesized to be more sensitive to Chk1 inhibition via synthetic lethality.

This clinical study consists of two phases, a Dose Escalation Phase 1 portion and a Cohort Expansion Phase 2 portion.

In the Dose Escalation Phase 1 portion, cohorts consisting initially of a single subject will receive escalating doses of SRA737, administered orally on a continuous daily dosing schedule in 28-day cycles. Once an SRA737-related Grade 2 toxicity is observed in a dose escalation cohort during Cycle 1, that cohort will be expanded to 3 to 6 subjects, and subsequent dose level cohorts will follow a rolling 6 design until the MTD has been identified.

In the Cohort Expansion Phase 2 portion, subjects with genetically-defined tumors that harbor genomic alterations linked to increased replication stress and that are hypothesized to be more sensitive to Chk1 inhibition will be prospectively enrolled into six indication-specific cohorts to explore the preliminary efficacy of SRA737. Subjects must have advanced or metastatic disease of one of the following types:

* castration-resistant prostate cancer (mCRPC);
* high grade serous ovarian cancer (HGSOC) without CCNE1 gene amplification;
* HGSOC with CCNE1 gene amplification (or alternative genetic alteration with similar functional effect);
* non-small cell lung cancer (NSCLC);
* head and neck squamous cell carcinoma (HNSCC) or squamous cell carcinoma of the anus (SCCA); and
* colorectal cancer (mCRC).

To qualify for enrolment in the Cohort Expansion Phase 2 portion, the subject's tumor must have a confirmed combination of mutations which are expected to confer sensitivity to Chk1 inhibition, determined by the Sponsor's review of genetic abnormalities detected in the following categories:

* Oncogenic drivers such as CCNE1 or MYC, etc.
* Genes involved in the DNA repair process including BRCA1, BRCA2, FANC genes, mismatch repair (MMR) genetic alterations and/or high microsatellite instability.
* Key tumor suppressor genes regulating G1 cell cycle progression/arrest such as TP53, RAD50, etc. For patients with HNSCC or SCCA, positive human papilloma virus (HPV) status is also considered for eligibility.
* Genetic indicators of replicative stress such as gain of function/amplification of CHEK1, ATR or other related genes.

Tumor genetics will be prospectively determined using Next-Generation Sequencing.

Eligibility criteria: Key Inclusion Criteria:

1. For Dose Escalation Only: any locally advanced or metastatic, histologically or cytologically proven solid tumor or NHL, relapsed after or progressing despite conventional treatment
2. Life expectancy of at least 12 weeks
3. World Health Organization (WHO) performance status of 0-1
4. Must meet select hematological and biochemical laboratory indices
5. Archival tumor tissue or accessible tumor and willingness to consent to a biopsy

Expansion Only:

1. Any locally advanced or metastatic malignancy of the following types for which no other conventional therapy is considered appropriate:

   * Metastatic Colorectal Cancer (CRC)
   * Platinum-resistant or intolerant High Grade Serious Ovarian Cancer (HGSOC)
   * Advanced Non-Small Cell Lung Cancer (NSCLC)
   * Metastatic Castration-Resistant Prostate Cancer (mCRPC)
   * Head and Neck Squamous Cell Carcinoma (HNSCC) or squamous cell carcinoma of the anus (SCCA).
   * Eligibility may be further restricted by the select number of prior regimens specific to each indication
2. Measurable disease per RECIST v1.1, or for mCRPC, evaluable disease per any of the following:

   * Measurable disease per RECIST v1.1
   * Increasing PSA
   * Circulating tumor cell (CTC) count of 5 or more cells per 7.5 ml of blood
3. Tumor tissue or ctDNA evidence that subject's tumor harbors a combination of mutations which are expected to confer sensitivity to Chk1 inhibition. Eligibility will be determined by the Sponsor's review of genetic abnormalities detected in genes in the following categories:

   * Oncogenic drivers such as MYC, CCNE1, etc.
   * Key tumor suppressor genes regulating G1 cell cycle progression/arrest such as RAD50, TP53, etc. For patients with NHSCC or SCCA, positive HPV status is also considered for eligibility.
   * The DDR pathway including BRCA1, BRCA2 and FANC. For patients with CRC, MMR genetic alterations and/or high microsatellite instability are also considered for eligibility.
   * Genetic indicators of replicative stress such as gain of function/amplification of Chk1 or ATR or other related gene.

Key Exclusion Criteria:

1. Received the following prior or current anticancer therapy:

   * Radiotherapy within the last 6 weeks
   * Endocrine therapy during the previous 4 weeks
   * Chemotherapy during the previous 4 weeks
   * Immunotherapy during the previous 6 weeks
   * Nitrosoureas or Mitomycin C during the previous 6 weeks
   * Other Investigational Medicinal Product during the 4 weeks before treatment
   * Any prior treatment with a Chk1 inhibitor or prior treatment with an ATR inhibitor within 6 months prior to receiving SRA737
2. Other malignancy within the past 2 years, except for adequately treated tumors
3. Ongoing toxic manifestations of previous treatments greater than NCI-CTCAE Grade 1
4. For Dose Escalation: new or progressing brain metastases. For Cohort Expansion: present or prior brain metastases
5. High medical risk because of nonmalignant systemic disease
6. Serologically positive for hepatitis B, hepatitis C or HIV
7. Serious cardiac condition, left ventricular ejection fraction \< 45% at baseline, history of cardiac ischemia within the past 6 months, or prior history of cardiac arrhythmia requiring treatment
8. Prior bone marrow transplant or extensive radiotherapy to greater than 25% of bone marrow within 8 weeks
9. Peanut allergy
10. QTcF\> 450 msec in adult males and \> 470 msec in adult females
11. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of SRA737
12. Inability to swallow capsules without chewing or crushing
13. Is a participant or plans to participate in another interventional clinical trial
14. Any other condition which in the Investigator's opinion would not make the subject a good candidate

Primary outcomes:
measure: Number of Subjects With Adverse Events as Assessed by CTCAE 4.03
timeFrame: Up to 30 days after last dose of SRA737
measure: Maximum Tolerated Dose of SRA737
timeFrame: Cycle 1 (28 days) in the Dose Escalation Phase
measure: Recommended Phase 2 Dose of SRA737
timeFrame: Up to 30 days after last dose of SRA737
measure: Disease Control Rate (DCR) of SRA737
timeFrame: Radiographic tumor assessments were performed every 2 cycles of therapy.
measure: Time to Progression (TTP)
timeFrame: Radiographic tumor assessments were performed every 2 cycles of therapy. Follow-up assessments were made every 16 weeks for subjects who had not progressed and had not initiated new anticancer therapy.
measure: Progression Free Survival (PFS)
timeFrame: Radiographic tumor assessments were performed every 2 cycles of therapy. Follow-up assessments were made every 16 weeks for subjects who had not progressed and had not initiated new anticancer therapy.
measure: Overall Survival (OS)
timeFrame: Follow-up assessments were made every 16 weeks for subjects who had not progressed and had not initiated new anticancer therapy.
Secondary outcomes:
Other outcomes:
Locations:
city: Sutton
country: United Kingdom
facility: Royal Marsden Hospital
state: London
city: Belfast
country: United Kingdom
facility: Belfast City Hospital
state: Northern Ireland
city: Headington
country: United Kingdom
facility: Oxford University Hospitals
state: Oxford
city: Cardiff
country: United Kingdom
facility: Velindre Cancer Centre - Cardiff
state: Whitchurch
city: Bebington
country: United Kingdom
facility: The Clatterbridge Cancer Centre
state: Wirral
city: Edinburgh
country: United Kingdom
facility: Western General Hospital
city: Glasgow
country: United Kingdom
facility: The Beatson West of Scotland Cancer Centre
city: Leeds
country: United Kingdom
facility: The Leeds Teaching Hospitals of St James University Hospital
city: Leicester
country: United Kingdom
facility: University Hospitals of Leicester
city: London
country: United Kingdom
facility: Guy's and St. Thomas
city: London
country: United Kingdom
facility: Sarah Cannon Research Institute
city: London
country: United Kingdom
facility: University College London Hospitals
city: Manchester
country: United Kingdom
facility: The Christie
city: Newcastle upon Tyne
country: United Kingdom
facility: Freeman Hospital
city: Sheffield
country: United Kingdom
facility: Sheffield Teaching Hospitals
Study officials:
References:
citation: Jin T, Xu L, Wang P, Hu X, Zhang R, Wu Z, Du W, Kan W, Li K, Wang C, Zhou Y, Li J, Liu T. Discovery and Development of a Potent, Selective, and Orally Bioavailable CHK1 Inhibitor Candidate: 5-((4-((3-Amino-3-methylbutyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)picolinonitrile. J Med Chem. 2021 Oct 28;64(20):15069-15090. doi: 10.1021/acs.jmedchem.1c00994. Epub 2021 Oct 19.